A股異動丨眾生藥業大漲超9% 將參與磷酸氯喹片治療肺炎的臨牀研究
格隆匯2月17日丨眾生藥業(002317.SZ)大漲超9%,報14.44元,總市值117.6億元。眾生藥業2月14日晚間公告稱,快速響應國家應對新型冠狀病毒肺炎疫情防治所需應急物資生產供應和保障的要求,迅速完成磷酸氯喹片的恢復生產工作並獲得《藥品補充申請批件》。公司作為臨牀研究合作單位積極參與磷酸氯喹片治療新型冠狀病毒肺炎的臨牀研究。眾生藥業主營業務是中成藥、化學藥、化學原料藥和中藥飲片的研發、生產和銷售,以及眼科的醫療服務和運營管理。公司、全資子公司華南藥業和先強藥業擁有片劑、膠囊劑、滴眼液、凍乾粉針等25個劑型、361個藥品生產批文,產品覆蓋眼科、心腦血管、呼吸、消化等重大疾病領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.